GSK2636771

貨號 Cat. No.
S8002
規格 Size
5~200mg
品牌 Brand
Selleckchem

Description

 



GSK2636771
Catalog No.S8002
 

1 Reviews

GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.


















Size Price Stock Quantity  


































10mM/1mLIn DMSO USD 592 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
5mg USD 340 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
10mg USD 466 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
50mg USD 1348 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
200mg USD 3112 In stock  
0
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 




Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw


 


Biological Activity







































Description GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.
Targets            
IC50            
In vitro GSK-2636771 shows selectively inhibitory activity in PTEN null cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. [1] GSK2636771 significantly decreases cell viability in p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines, and leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines. [2]
In vivo GSK-2636771 decreases phosphorylated protein kinase Akt (Ser473) levels in these xenograft models. GSK-2636771 (100 mg/kg) do not increase glucose/insulin levels in mice. [1]
Features  

Protocol(Only for Reference)


Cell Assay: [2]





















Cell lines p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines.
Concentrations ~10 μM
Incubation Time 72 hours
Method Cells are plated in 96-well microtiter plates at densities ranging from 1,500 to 15,000 cells/well, optimized for untreated control cells to be 80-90% confluent at the endpoint of the experiment. After 24 h, cells are treated with serial dilutions (100pM to 10μM) of GSK2636771. Cell viability is assessed after 72 h of treatment by incubation with CellTiter Blue for 1.5 h. The drug concentration requires for survival of 50% of cells relative to untreated cells (surviving fraction 50, SF50) is determined using GraphPad Prism version 5.0d. Cell lines that fails to achieve the SF50 to a given drug are nominally assigned as the highest concentration screened (i.e. 10μM). At least three independent experiments in triplicate per cell line targeted drug are performed. Association between a mutation and response to a targeted agent is determined using a Fisher’s exact test (GraphPad Prism), and a two-tailed P value <0.05 is considered statistically significant.

1


References


Clinical Trial Information( data from http://clinicaltrials.gov)





















NCT Number Recruitment Conditions Sponsor

/Collaborators
Start Date Phases
NCT01458067 Recruiting Cancer GlaxoSmithKline 2011-11 Phase 1

Chemical Information


Download GSK2636771 SDF


 

















Molecular Weight (MW) 433.42
Formula

C22H22F3N3O3


CAS No. 1372540-25-4















Storage 2 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A

 





















Solubility (25°C) * In vitro DMSO 28 mg/mL (64 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.


 








Chemical Name 1H-Benzimidazole-4-carboxylic acid, 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-(4-morpholinyl)-

 

Preparing Stock Solutions



















Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.43342 4.3342 8.6684 13.0026


Customer Reviews (1)




































Click to enlarge
Rating

 


Source Dr Antonino Maria Spartà from University of Bologna.GSK2636771 purchased from Selleck
Method MTT
Cell Lines ALL-SIL cells
Concentrations  
Incubation Time 48 h
Results PI3K inhibitor GSK2636771 demonstrated to be effective on ALL-SIL cells, showed an IC50 in the lower micromolar range.

詢價 / 洽詢此產品

同品牌其他產品

回到產品列表

▲ LINE
諮詢